STAAR SURGICAL CO
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $STAA in the last 7 days.
No SEC Form 4 filings for $STAA in the last 30 days.
See all $STAA insider activity →STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, driven by China and Americas growth. Net income was $8.1M, or $0.16 per share, with adjusted EBITDA at $20.0M. Gross margin improved to 74.5%. Management highlighted EVO Plus success in China and U.S. market share gains, but noted risks from China tariffs and supply chain constraints.
STAAR Surgical (STAA) shares fell about 8% after Q2 results and sentiment cooled. The company reported sales and EPS above analysts’ estimates but cited uneven refractive market conditions and ongoing tariff and currency headwinds, especially in Asia. Stifel cut its price target to $28 from $31 (Hold) due to concerns about China. Shares closed at $24.15.
Simply Wall St reports STAAR Surgical (STAA) returned to profitability in Q2 2026 under new CEO Warren Foust. The company posted $93.54M sales and $8.06M net income, versus a loss a year earlier. For H1 2026, sales rose to $187.06M and EPS turned profitable. The article cites 2029 targets of $400M revenue and $36.5M earnings.
Recent STAA coverage spans earnings, financial news and market movers.
Earnings beat expectations and show strong growth in China and the Americas, likely supporting short‑term upside.
The selloff is tied to mixed demand signals despite beating sales and EPS estimates, plus a Stifel price-target cut citing fragile China conditions.
Profitability rebound and a new CEO narrative may support near-term earnings expectations, but sustainability in China volumes and margins remains the key risk.
China demand and EVO Plus supply execution are the near-term swing factors, with margin risk tied to shifting Chinese manufacturing to Switzerland.
Analyst PT reduction after an earnings setup where revenue beat but EPS missed, with no formal company guidance.
alphai scores every news story that mentions STAA with an AI model for sentiment and relevance, and aggregates insider trades from STAAR SURGICAL CO's SEC EDGAR Form 4 filings. Figures refresh continuously.
STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, driven by China and Americas growth. Net income was $8.1M, or $0.16 per share, with adjusted EBITDA at $20.0M. Gross margin improved to 74.5%. Management highlighted EVO Plus success in China and U.S. market share gains, but noted risks from China tariffs and supply chain constraints.
3 min readSTAAR Surgical (STAA) shares fell about 8% after Q2 results and sentiment cooled. The company reported sales and EPS above analysts’ estimates but cited uneven refractive market conditions and ongoing tariff and currency headwinds, especially in Asia. Stifel cut its price target to $28 from $31 (Hold) due to concerns about China. Shares closed at $24.15.
4 min readSimply Wall St reports STAAR Surgical (STAA) returned to profitability in Q2 2026 under new CEO Warren Foust. The company posted $93.54M sales and $8.06M net income, versus a loss a year earlier. For H1 2026, sales rose to $187.06M and EPS turned profitable. The article cites 2029 targets of $400M revenue and $36.5M earnings.
4 min readSTAAR Surgical said EVO Plus adoption should support China revenue growth, with Q3 and Q4 expected to be sequentially softer than Q2. The company plans to shift all China-destined manufacturing to Switzerland by year-end to reduce tariff margin pressure. It also plans broader lens product expansion and new clinical studies. Shares last traded at $24.76.
4 min readJefferies cut its price target for STAAR Surgical (STAA) to $28 from $29 but kept a Hold rating after the company’s Q2 2026 results. Revenue was $93.5M, flat QoQ and 4% above consensus. China sales were $52.3M. Gross margin was 74.5%, but EPS was $0.16 vs $0.22 consensus.
3 min readSTAAR Surgical (STAA) reported Q2 2026 net sales of $93.5 million, up 111% year over year, driven by China. China sales were $52.3 million. Gross margin rose to 74.5%. Operating income was $10.1 million versus a $30.0 million loss a year earlier. Net income was $8.1 million ($0.16/share).
4 min readSTAAR Surgical (NASDAQ:STAA) reported Q2 CY2026 revenue of $93.54 million, up 111% year on year and 3.3% above Wall Street estimates, according to the company. GAAP EPS was $0.16, up from -$0.34 a year earlier, and above consensus. The stock fell 8% to $23.38 after results. Analysts expect revenue to rise 2.7% over 12 months.
5 min readSTAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STAAR Surgical Reports Second Quarter 2026 Results Net Sales of $93.5 million, up 111% Y/Y Net Income of $8.1 million, with GAAP EPS of $0.16 Adjusted EBITDA 1 of $20.0 million, or $0.39 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern LAKE FOREST
6 min readSTAAR Surgical (NASDAQ: STAA) is set to report Q2 earnings Wednesday after market close. The company’s prior quarter revenue was $93.52 million, up 120% year over year. For the upcoming quarter, analysts expect revenue to rise 104% year over year. The article cites an average analyst price target of $28.70 versus a $25.31 share price.
4 min readMasimo and Staar Surgical appointed new executives amid prior deal and proxy turmoil. Masimo named Tim Benner president under Danaher ownership, succeeding Katie Szyman after Masimo’s $9.9B Danaher acquisition. Staar made Warren Foust permanent CEO after a failed $1.6B Alcon sale. Staar Q1 revenue rose to $93.5M; Q2 revenue expected over $90M.
4 min read
